全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

Predicting Antidepressant Treatment Response Using Machine Learning: A Multimodal Analysis of Clinical and Genetic Data

DOI: 10.4236/oalib.1113958, PP. 1-26

Subject Areas: Psychiatry & Psychology

Keywords: Antidepressant Response, Machine Learning, Clinical Data, Genetic Biomarkers, Precision Psychiatry, Random Forest, Logistic Regression, SHAP, Threshold Optimization

Full-Text   Cite this paper   Add to My Lib

Abstract

Accurately predicting individual responses to antidepressant treatment is a critical step toward achieving personalized psychiatry and minimizing the traditional trial-and-error approach in clinical practice. This study applies a comprehensive machine learning framework to predict antidepressant treatment outcomes by integrating both clinical and genetic data. Four supervised learning models were developed and evaluated: Random Forest, XGBoost, Support Vector Machine (SVM), and Logistic Regression. The dataset consisted of balanced groups of responders and non-responders, incorporating key clinical variables such as age, body mass index (BMI), baseline depression severity measured by HAMD scores, illness duration, sleep quality, early life stress, and anxiety comorbidity, along with genetic polymorphisms including the 5HTTLPR variant and other serotonin-related markers. Extensive data preprocessing, feature engineering, and hyperparameter tuning using GridSearchCV with five-fold cross-validation were employed to ensure model robustness and reliability. Model evaluation was based on multiple performance metrics, including accuracy, precision, recall, F1 score, and ROC AUC, supported by confusion matrices and visualizations of ROC and precision-recall curves. Feature importance was systematically analyzed using Random Forest rankings, Logistic Regression coefficients, and SHAP (SHapley Additive exPlanations) values to provide model interpretability and clinical insight. Among the evaluated models, Random Forest and Logistic Regression demonstrated the most balanced predictive capabilities. Clinical features, particularly baseline depression severity, age, and early life stress, emerged as the most influential predictors, while the genetic marker 5HTTLPR also showed a significant contribution to treatment response classification. The study further refined clinical applicability through threshold optimization, enhancing recall performance to prioritize responder detection. These findings highlight the potential of machine learning to support personalized treatment strategies in psychiatric care. 

Cite this paper

Filippis, R. D. and Foysal, A. A. (2025). Predicting Antidepressant Treatment Response Using Machine Learning: A Multimodal Analysis of Clinical and Genetic Data. Open Access Library Journal, 12, e13958. doi: http://dx.doi.org/10.4236/oalib.1113958.

References

[1]  Proudman, D., Greenberg, P. and Nellesen, D. (2021) The Growing Burden of Major Depressive Disorders (MDD): Implica-tions for Researchers and Policy Makers. PharmacoEconomics, 39, 619-625. https://doi.org/10.1007/s40273-021-01040-7
[2]  Santomauro, D.F., Vos, T., Whiteford, H.A., Chisholm, D., Saxena, S. and Ferrari, A.J. (2024) Service Coverage for Major Depressive Disorder: Estimated Rates of Minimally Adequate Treatment for 204 Countries and Territories in 2021. The Lancet Psychiatry, 11, 1012-1021. https://doi.org/10.1016/s2215-0366(24)00317-1
[3]  Moitra, M., Santomauro, D., Collins, P.Y., Vos, T., Whiteford, H., Saxena, S., et al. (2022) The Global Gap in Treatment Coverage for Major Depressive Disorder in 84 Countries from 2000-2019: A Systematic Review and Bayesian Meta-Regression Analysis. PLOS Medicine, 19, e1003901. https://doi.org/10.1371/journal.pmed.1003901
[4]  Santomauro, D.F., Mantilla Herrera, A.M., Shadid, J., Zheng, P., Ashbaugh, C., Pigott, D.M., et al. (2021) Global Prevalence and Burden of Depressive and Anxiety Disorders in 204 Coun-tries and Territories in 2020 due to the COVID-19 Pandemic. The Lancet, 398, 1700-1712. https://doi.org/10.1016/s0140-6736(21)02143-7
[5]  Locher, C., Koechlin, H., Zion, S.R., Werner, C., Pine, D.S., Kirsch, I., et al. (2017) Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibi-tors, and Placebo for Common Psychiatric Disorders among Children and Adolescents: A Systematic Review and ME-TA-Analysis. JAMA Psychiatry, 74, 1011-1020. https://doi.org/10.1001/jamapsychiatry.2017.2432
[6]  Dell’Osso, B., Buoli, M., Baldwin, D.S. and Altamura, A.C. (2009) Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) in Anxiety Dis-orders: A Comprehensive Review of Their Clinical Efficacy. Human Psychopharmacology: Clinical and Experimental, 25, 17-29. https://doi.org/10.1002/hup.1074
[7]  Montano, C.B., Jackson, W.C., Vanacore, D. and Weisler, R. (2023) Con-siderations When Selecting an Antidepressant: A Narrative Review for Primary Care Providers Treating Adults with De-pression. Postgraduate Medicine, 135, 449-465. https://doi.org/10.1080/00325481.2023.2189868
[8]  Katon, W.J. (2011) Epidemiology and Treatment of Depression in Patients with Chronic Medical Illness. Dialogues in Clinical Neurosci-ence, 13, 7-23. https://doi.org/10.31887/dcns.2011.13.1/wkaton
[9]  Vos, T., Haby, M.M., Barendregt, J.J., Kruijshaar, M., Corry, J. and Andrews, G. (2004) The Burden of Major Depression Avoidable by Longer-Term Treatment Strategies. Archives of General Psychiatry, 61, 1097-1103. https://doi.org/10.1001/archpsyc.61.11.1097
[10]  Kumar, K.P.S., Sri-vastava, S., Paswan, S. and Dutta, A.S. (2012) Depression-Symptoms, Causes, Medications and Therapies. The Pharma In-novation, 1, 37-51.
[11]  McIntyre, R.S. and O’Donovan, C. (2004) The Human Cost of Not Achieving Full Remission in De-pression. Canadian Journal of Psychiatry, 49, 10S-16S.
[12]  Zeier, Z., Carpenter, L.L., Kalin, N.H., Rodriguez, C.I., McDon-ald, W.M., Widge, A.S., et al. (2018) Clinical Implementation of Pharmacogenetic Decision Support Tools for Antidepressant Drug Prescribing. American Journal of Psychiatry, 175, 873-886. https://doi.org/10.1176/appi.ajp.2018.17111282
[13]  Eap, C.B., Gründer, G., Baumann, P., Ansermot, N., Conca, A., Corruble, E., et al. (2021) Tools for Optimising Pharmacotherapy in Psychiatry (Therapeutic Drug Monitoring, Molecular Brain Imaging and Pharmacogenetic Tests): Focus on Antidepressants. The World Journal of Biological Psychiatry, 22, 561-628. https://doi.org/10.1080/15622975.2021.1878427
[14]  Huang, M. and Pan, H. (2023) Pharmacogenomic Pro-filing to Tailor Antidepressant Therapy: Improving Treatment Outcomes and Reducing Adverse Drug Reactions in Major Depressive Disorder. SHIFAA, 2023, 19-31. https://doi.org/10.70470/shifaa/2023/003
[15]  Maj, M., Stein, D.J., Parker, G., Zimmerman, M., Fava, G.A., De Hert, M., et al. (2020) The Clinical Characterization of the Adult Patient with Depression Aimed at Personalization of Management. World Psychiatry, 19, 269-293. https://doi.org/10.1002/wps.20771
[16]  Milic, J., Vucurovic, M., Jovic, D., Stankovic, V., Grego, E., Jankovic, S., et al. (2025) Exploring the Potential of Precision Medicine in Neuropsychiatry: A Commentary on New Insights for Tailored Treatments Based on Genetic, Environmental, and Lifestyle Factors. Genes, 16, Article 371. https://doi.org/10.3390/genes16040371
[17]  Zanardi, R., Prestifilippo, D., Fabbri, C., Colombo, C., Maron, E. and Serretti, A. (2020) Precision Psychiatry in Clinical Practice. International Journal of Psychiatry in Clinical Practice, 25, 19-27. https://doi.org/10.1080/13651501.2020.1809680
[18]  Manchia, M., Pisanu, C., Squassina, A. and Carpiniello, B. (2020) Challenges and Future Prospects of Precision Medicine in Psychiatry. Pharmacogenomics and Personalized Medicine, 13, 127-140. https://doi.org/10.2147/pgpm.s198225
[19]  Comai, S., Manchia, M., Bosia, M., Miola, A., Poletti, S., Benedetti, F., et al. (2025) Moving toward Precision and Personalized Treatment Strategies in Psychia-try. International Journal of Neuropsychopharmacology, 28, pyaf025. https://doi.org/10.1093/ijnp/pyaf025
[20]  Gandal, M.J., Leppa, V., Won, H., Parikshak, N.N. and Geschwind, D.H. (2016) The Road to Precision Psychiatry: Translating Genetics into Disease Mechanisms. Nature Neuroscience, 19, 1397-1407. https://doi.org/10.1038/nn.4409
[21]  Orphanidou, C. and Wong, D. (2017) Machine Learning Models for Multidimensional Clinical Data. In: Khan, S., Zomaya, A. and Abbas, A., Eds., Handbook of Large-Scale Distributed Computing in Smart Healthcare, Springer, 177-216. https://doi.org/10.1007/978-3-319-58280-1_8
[22]  Mirza, B., Wang, W., Wang, J., Choi, H., Chung, N.C. and Ping, P. (2019) Machine Learning and Integrative Analysis of Biomedical Big Data. Genes, 10, Article 87. https://doi.org/10.3390/genes10020087
[23]  Kiranyaz, S., Ince, T. and Gabbouj, M. (2014) Multidimensional Particle Swarm Optimization for Machine Learning and Pattern Recognition. Springer.
[24]  Ogbu, A.D., Iwe, K.A., Ozowe, W. and Ikevuje, A.H. (2024) Advances in Machine Learning-Driven Pore Pressure Prediction in Complex Geological Settings. Com-puter Science & IT Research Journal, 5, 1648-1665. https://doi.org/10.51594/csitrj.v5i7.1350
[25]  Chekroud, A.M., Bondar, J., Delgadillo, J., Doherty, G., Wasil, A., Fokkema, M., et al. (2021) The Promise of Machine Learning in Predicting Treatment Outcomes in Psychiatry. World Psychiatry, 20, 154-170. https://doi.org/10.1002/wps.20882
[26]  Bobo, W.V., Van Ommeren, B. and Athreya, A.P. (2022) Machine Learning, Pharmacogenomics, and Clinical Psychiatry: Predicting An-tidepressant Response in Patients with Major Depressive Disorder. Expert Review of Clinical Pharmacology, 15, 927-944. https://doi.org/10.1080/17512433.2022.2112949
[27]  Athreya, A.P., Iyer, R., Wang, L., Weinshilboum, R.M. and Bobo, W.V. (2019) Integration of Machine Learning and Pharmacogenomic Biomarkers for Predicting Response to Antidepressant Treatment: Can Computational Intelligence Be Used to Augment Clinical Assessments? Pharmacogenomics, 20, 983-988. https://doi.org/10.2217/pgs-2019-0119
[28]  Rutledge, R.B., Chekroud, A.M. and Huys, Q.J. (2019) Machine Learning and Big Data in Psychiatry: Toward Clinical Applications. Current Opinion in Neurobiology, 55, 152-159. https://doi.org/10.1016/j.conb.2019.02.006
[29]  Lin, E., Lin, C. and Lane, H. (2021) Machine Learning and Deep Learn-ing for the Pharmacogenomics of Antidepressant Treatments. Clinical Psychopharmacology and Neuroscience, 19, 577-588. https://doi.org/10.9758/cpn.2021.19.4.577
[30]  Nikolodimou, V. and Agapow, P. (2020) Using Machine-Learning Tech-niques to Identify Responders vs. Non-Responders in Randomized Clinical Trials. medRxiv.
[31]  Bai, X., Feng, M., Ma, W. and Wang, S. (2025) Predicting the Efficacy of Bevacizumab on Peritumoral Edema Based on Imaging Features and Ma-chine Learning. Scientific Reports, 15, Article No. 15990. https://doi.org/10.1038/s41598-025-00758-0
[32]  Georgoula, M. (2024) Application of Machine Learning Methods to Predict Critical Multiple Myeloma Events. Ph.D. Thesis, School of Electrical and Computer Engineering.
[33]  McShane, L.M., Cavenagh, M.M., Lively, T.G., Eberhard, D.A., Bigbee, W.L., Wil-liams, P.M., et al. (2013) Criteria for the Use of Omics-Based Predictors in Clinical Trials: Explanation and Elaboration. BMC Medicine, 11, Article No. 220. https://doi.org/10.1186/1741-7015-11-220
[34]  Saito, T. and Rehmsmeier, M. (2015) The Precision-Recall Plot Is More Informative than the ROC Plot When Evaluating Binary Classifiers on Imbalanced Datasets. PLOS ONE, 10, e0118432. https://doi.org/10.1371/journal.pone.0118432
[35]  Davis, J. and Goadrich, M. (2006) The Relationship between Precision-Recall and ROC Curves. Proceedings of the 23rd International Conference on Machine Learning—ICML‘06, Pittsburgh, 25-29 June 2006, 233-240. https://doi.org/10.1145/1143844.1143874
[36]  Tharwat, A. (2020) Classification Assessment Methods. Applied Computing and Informatics, 17, 168-192. https://doi.org/10.1016/j.aci.2018.08.003
[37]  Sherbourne, C.D., Hays, R.D. and Wells, K.B. (1995) Personal and Psy-chosocial Risk Factors for Physical and Mental Health Outcomes and Course of Depression among Depressed Patients. Jour-nal of Consulting and Clinical Psychology, 63, 345-355. https://doi.org/10.1037//0022-006x.63.3.345
[38]  Shi, L., Lu, Z., Que, J., Huang, X., Liu, L., Ran, M., et al. (2020) Prevalence of and Risk Factors Associated with Mental Health Symptoms among the General Population in China during the Coronavirus Disease 2019 Pandemic. JAMA Network Open, 3, e2014053. https://doi.org/10.1001/jamanetworkopen.2020.14053
[39]  Hendrie, H.C., Lindgren, D., Hay, D.P., Lane, K.A., Gao, S., Purnell, C., et al. (2013) Comorbidity Profile and Healthcare Utilization in Elderly Patients with Serious Mental Illnesses. The American Journal of Geriatric Psychiatry, 21, 1267-1276. https://doi.org/10.1016/j.jagp.2013.01.056
[40]  Delgadillo, J., Moreea, O. and Lutz, W. (2016) Different People Respond Differently to Therapy: A Demonstration Using Patient Profiling and Risk Stratification. Behaviour Research and Therapy, 79, 15-22. https://doi.org/10.1016/j.brat.2016.02.003
[41]  Pearson, R. (2011) Exploring Data. Oxford University Press.
[42]  Vesanto, J. and Alhoniemi, E. (2000) Clustering of the Self-Organizing Map. IEEE Transactions on Neural Net-works, 11, 586-600. https://doi.org/10.1109/72.846731
[43]  Cifci, A. (2025) Interpretable Prediction of a Decentralized Smart Grid Based on Machine Learning and Explainable Artificial Intelligence. IEEE Access, 13, 36285-36305. https://doi.org/10.1109/access.2025.3543759
[44]  Demir, S. and Sahin, E.K. (2025) An Innovative Machine Learning Approach for Slope Stability Prediction by Combining Shap Interpretability and Stacking Ensemble Learning. Environmental Science and Pollution Research, 32, 12827-12843. https://doi.org/10.1007/s11356-025-36406-3
[45]  Elhishi, S., Elashry, A.M. and El-Metwally, S. (2023) Unboxing Machine Learning Models for Concrete Strength Prediction Using Xai. Scientific Reports, 13, Article No. 19892. https://doi.org/10.1038/s41598-023-47169-7
[46]  Eskandari, H., Saadatmand, H., Ramzan, M. and Mousapour, M. (2024) Innovative Framework for Accurate and Transparent Forecasting of Energy Consumption: A Fusion of Feature Selection and Interpretable Machine Learning. Applied Energy, 366, Article ID: 123314. https://doi.org/10.1016/j.apenergy.2024.123314
[47]  Chinnaraju, A. (2025) Explainable AI (XAI) for Trustworthy and Transparent Decision-Making: A Theoretical Framework for AI Interpretability. World Journal of Advanced Engineering Technology and Sciences, 14, 170-207. https://doi.org/10.30574/wjaets.2025.14.3.0106
[48]  Gholampour, S. (2024) Impact of Nature of Medical Data on Machine and Deep Learning for Imbalanced Datasets: Clinical Validity of SMOTE Is Questionable. Machine Learning and Knowledge Extraction, 6, 827-841. https://doi.org/10.3390/make6020039
[49]  Emi-Johnson, O., Nkrumah, K., Folasole, A. and Kolade Amusa, T. (2023) Optimizing Machine Learning for Imbalanced Classification: Applications in Us Healthcare, Finance, and Security. Interna-tional Journal of Engineering Technology Research & Management, 7, 89-106.
[50]  Kunti, R. (2021) Classification of Bio-medical Data with Class Imbalance. Ph.D. Thesis, Kanazawa University.
[51]  Shipe, M.E., Deppen, S.A., Farjah, F. and Grogan, E.L. (2019) Developing Prediction Models for Clinical Use Using Logistic Regression: An Overview. Journal of Tho-racic Disease, 11, S574-S584. https://doi.org/10.21037/jtd.2019.01.25
[52]  Fleming, T.R. (2011) Addressing Missing Data in Clinical Trials. Annals of Internal Medicine, 154, 113-117. https://doi.org/10.7326/0003-4819-154-2-201101180-00010
[53]  O’Kelly, M. and Ratitch, B. (2014) Clinical Trials with Missing Data. Wiley. https://doi.org/10.1002/9781118762516
[54]  Jarrett, R.B. and Thase, M.E. (2010) Comparative Efficacy and Durability of Continuation Phase Cognitive Therapy for Preventing Recurrent Depression: Design of a Dou-ble-Blinded, Fluoxetine- and Pill Placebo-Controlled, Randomized Trial with 2-Year Follow-up. Contemporary Clinical Trials, 31, 355-377. https://doi.org/10.1016/j.cct.2010.04.004
[55]  Nobre, A.C. (2020) Cognitive Neuroscience. In: Geddes, J.R., et al., Eds., New Oxford Textbook of Psychiatry, Oxford University Press, 154-169. https://doi.org/10.1093/med/9780198713005.003.0017
[56]  Keeling, N. (2016) Payer Perspectives on Preemptive Pharmacogenetic Testing. https://egrove.olemiss.edu/etd/735/
[57]  Whyte, E.M., Dew, M.A., Gildengers, A., Lenze, E.J., Bharucha, A., Mulsant, B.H., et al. (2004) Time Course of Response to Antidepressants in Late-Life Major Depression. Drugs & Aging, 21, 531-554. https://doi.org/10.2165/00002512-200421080-00004
[58]  Fornaro, M., Anastasia, A., Novello, S., Fusco, A., Pariano, R., De Berardis, D., et al. (2019) The Emergence of Loss of Efficacy during Antidepressant Drug Treatment for Major Depressive Disorder: An Integrative Review of Evidence, Mechanisms, and Clinical Implications. Phar-macological Research, 139, 494-502. https://doi.org/10.1016/j.phrs.2018.10.025
[59]  Haddad, P.M., Talbot, P.S., An-derson, I.M. and McAllister-Williams, R.H. (2015) Managing Inadequate Antidepressant Response in Depressive Illness. British Medical Bulletin, 115, 183-201. https://doi.org/10.1093/bmb/ldv034
[60]  Sartorius, N., Baghai, T.C., Baldwin, D.S., Barrett, B., Brand, U., Fleischhacker, W., et al. (2007) Antidepressant Medications and Other Treatments of Depressive Disorders: A CINP Task Force Report Based on a Review of Evidence. The International Journal of Neuropsychopharmacolo-gy, 10, S1-S207. https://doi.org/10.1017/s1461145707008255
[61]  Lapolla, T., Saltiel, P. and Silvershein, D. (2015) Major Depressive Disorder: Mechanism-Based Prescribing for Personalized Medicine. Neuropsychiatric Disease and Treat-ment, 11, 875-888. https://doi.org/10.2147/ndt.s73261
[62]  Koch, E., Pardiñas, A.F., O’Connell, K.S., Selvaggi, P., Camacho Collados, J., Babic, A., et al. (2024) How Real-World Data Can Facilitate the Development of Precision Medicine Treatment in Psychiatry. Biological Psychiatry, 96, 543-551. https://doi.org/10.1016/j.biopsych.2024.01.001
[63]  Baldwin, H., Loebel-Davidsohn, L., Oliver, D., Salazar de Pablo, G., Stahl, D., Riper, H., et al. (2022) Real-World Implementation of Precision Psychiatry: A Systematic Review of Barriers and Facilitators. Brain Sciences, 12, Article 934. https://doi.org/10.3390/brainsci12070934
[64]  Roy-Byrne, P.P., Sherbourne, C.D., Craske, M.G., Stein, M.B., Katon, W., Sullivan, G., et al. (2003) Moving Treatment Research from Clinical Trials to the Real World. Psychiatric Services, 54, 327-332. https://doi.org/10.1176/appi.ps.54.3.327
[65]  Simon, G. (1995) Cost-Effectiveness Comparisons Using “Real World” Randomized Trials: The Case of New Antidepressant Drugs. Journal of Clinical Epidemiology, 48, 363-373. https://doi.org/10.1016/0895-4356(94)00141-c
[66]  Meehan, A.J., Lewis, S.J., Fazel, S., Fusar-Poli, P., Steyerberg, E.W., Stahl, D., et al. (2022) Clinical Prediction Models in Psychiatry: A Sys-tematic Review of Two Decades of Progress and Challenges. Molecular Psychiatry, 27, 2700-2708. https://doi.org/10.1038/s41380-022-01528-4
[67]  Bzdok, D. and Meyer-Lindenberg, A. (2018) Machine Learning for Precision Psychiatry: Opportunities and Challenges. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 3, 223-230. https://doi.org/10.1016/j.bpsc.2017.11.007
[68]  Fusar-Poli, P., Hijazi, Z., Stahl, D. and Steyerberg, E.W. (2018) The Science of Prognosis in Psychiatry. JAMA Psychiatry, 75, 1289-1297. https://doi.org/10.1001/jamapsychiatry.2018.2530

Full-Text


Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133